-+ 0.00%
-+ 0.00%
-+ 0.00%

Nippon Shinyaku reports five-year data for DMD drug brogidirsen in exon 44-skipping trial

PUBT·10/01/2026 02:01:12
Listen to the news
Nippon Shinyaku reports five-year data for DMD drug brogidirsen in exon 44-skipping trial
  • Nippon Shinyaku disclosed five-year data for brogidirsen in Duchenne muscular dystrophy; results were presented at the World Muscle Society 2026 Congress.
  • Long-term findings indicated motor function was maintained or improved in ambulant patients; upper-limb function was maintained across all participants.
  • Safety profile appeared supportive, with no serious treatment-related adverse events, no infusion-related anaphylaxis, no discontinuations tied to side effects.
  • The ongoing open-label extension continues; a global Phase II study is underway through its subsidiary NS Pharma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.